2D-DIGE as a strategy to identify serum protein biomarkers to monitor pharmacological efficacy in dopamine-dictated states of Parkinson’s disease and schizophrenia

References

• de LauLMBretelerMMEpidemiology of Parkinson’s diseaseLancet Neurol20065652553510.1016/S1474-4422(06)70471-916713924
   PubMed Web of Science ®Google Scholar
• NussbaumRLEllisCEAlzheimer’s disease and Parkinson’s diseaseN Engl J Med20033481413561364. Erratum in: N Engl J Med 2003 348 25 258810.1056/NEJM2003ra02000312672864
   PubMed Web of Science ®Google Scholar
• TwelvesDPerkinsKSCounsellCSystematic review of incidence studies of Parkinson’s diseaseMov Disord2003181193110.1002/mds.1030512518297
   PubMed Web of Science ®Google Scholar
• Von CampenhausenSBornscheinBWickRPrevalence and incidence of Parkinson’s disease in EuropeEur Neuropsychopharmacol200515447349010.1016/j.euroneuro.2005.04.00715963700
   PubMed Web of Science ®Google Scholar
• MuangpaisanWHoriHBrayneCSystematic review of the prevalence and incidence of Parkinson’s disease in AsiaJ Epidemiol200919628129319801887
   PubMed Web of Science ®Google Scholar
• Van Den EedenSKTannerCMBernsteinALIncidence of Parkinson’s disease: variation by age, gender, and race/ethnicityAm J Epidemiol2003157111015102212777365
   PubMed Web of Science ®Google Scholar
• PringsheimTJetteNFrolkisAThe prevalence of Parkinson’s disease: a systematic review and meta-analysisMov Disord201429131583159010.1002/mds.2594524976103
   PubMed Web of Science ®Google Scholar
• DriverJALogroscinoGGazianoJMKurthTIncidence and remaining lifetime risk of Parkinson disease in advanced ageNeurology200972543243810.1212/01.wnl.0000341769.50075.bb19188574
   PubMed Web of Science ®Google Scholar
• de LauLMGiesbergenPCde RijkMCIncidence of parkinsonism and Parkinson disease in a general population: the rotterdam studyNeurology20046371240124415477545
   PubMed Web of Science ®Google Scholar
• BennettDABeckettLAMurrayAMPrevalence of parkinsonian signs and associated mortality in a community population of older peopleN Engl J Med19963342717610.1056/NEJM1996011133402028531961
   PubMed Web of Science ®Google Scholar
• PicchioniMMMurrayRMSchizophreniaBMJ20073357610919510.1136/bmj.39227.616447.BE17626963
   PubMed Web of Science ®Google Scholar
• van OsJKapurSSchizophreniaLancet2009374969063564510.1016/S0140-6736(09)60995-819700006
   PubMed Web of Science ®Google Scholar
• CastleDWesselySDerGMurrayRMThe incidence of operationally defined schizophrenia in Camberwell, 1965–84Br J Psychiatry19911597907941790446
   PubMed Web of Science ®Google Scholar
• KumraSShawMMerkaPNakayamaEAugustinRChildhood-onset schizophrenia: research updateCan J Psychiatry2001461092393010.1177/07067437010460100411816313
   PubMed Web of Science ®Google Scholar
• JablenskyASartoriusNErnbergGSchizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country studyPsychol Med Monogr19922019710.1017/S0264180100000904
   PubMedGoogle Scholar
• KirkbrideJBFearonPMorganCNeighbourhood variation in the incidence of psychotic disorders in Southeast LondonSoc Psychiatry Psychiatr Epidemiol200742643844510.1007/s00127-007-0193-017473901
   PubMed Web of Science ®Google Scholar
• LozanoRNaghaviMForemanKGlobal and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010Lancet201238098592095212810.1016/S0140-6736(12)61728-023245604
   PubMed Web of Science ®Google Scholar
• XiaRMaoZHProgression of motor symptoms in Parkinson’s diseaseNeurosci Bull2012281394810.1007/s12264-012-1050-z22233888
   PubMed Web of Science ®Google Scholar
• BirtwistleJBaldwinDRole of dopamine in schizophrenia and Parkinson’s diseaseBr J Nurs199871483283483683884110.12968/bjon.1998.7.14.56369849144
   PubMedGoogle Scholar
• YabeIOhtaMEgashiraTEffectiveness of zonisamide in a patient with Parkinson’s disease and various levodopa-induced psychotic symptomsNeurol Clin Neurosci20142620120310.1111/ncn3.126
   Google Scholar
• BohlegaSAAl-FoghomNBDrug-induced Parkinson`s disease. A clinical reviewNeurosciences (Riyadh)201318321522123887211
   PubMed Web of Science ®Google Scholar
• GuptaAKSwarnkarSKhungerGKDopamine based pharmacotherapeutics of schizophrenia and Parkinson’s disease: two ends of one spectrumAnn Pharmacol Pharm2017201721109
   Google Scholar
• FernándezCPAguilarSViçensVECT in a patient with Parkinson’s disease and schizophrenia, with dopamine transporter visualization using 123I-ioflupane SPETJ Neural Transm2011118464765010.1007/s00702-011-0615-821359970
   PubMed Web of Science ®Google Scholar
• ZahodneLBFernandezHHPathophysiology and treatment of psychosis in Parkinson’s disease: a reviewDrugs Aging200825866568210.2165/00002512-200825080-0000418665659
   PubMed Web of Science ®Google Scholar
• FernandezHHTrieschmannMEFriedmanJHTreatment of psychosis in Parkinson’s disease: safety considerationsDrug Saf200326964365910.2165/00002018-200326090-0000412814332
   PubMed Web of Science ®Google Scholar
• NowakDAConnemannBJAlanMSpitzerMSensorimotor dysfunction of grasping in schizophrenia: a side effect of antipsychotic treatment?J Neurol Neurosurg Psychiatry200677565065710.1136/jnnp.2005.08474916614027
   PubMed Web of Science ®Google Scholar
• BlanchetPJNormandeauLRompréPHComparing three screening tools for drug-induced parkinsonism in patients with advanced schizophrenia: a pilot studySchizophr Res20121371–323023310.1016/j.schres.2012.01.01322309978
   PubMed Web of Science ®Google Scholar
• RavinaBMarderKFernandezHHDiagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work groupMov Disord20072281061106810.1002/mds.2138217266092
   PubMed Web of Science ®Google Scholar
• HariprasadGHariprasadRKumarLApolipoprotein A1 as a potential biomarker in the ascitic fluid for the differentiation of advanced ovarian cancersBiomarkers201318653254110.3109/1354750X.2013.82256123902290
   PubMed Web of Science ®Google Scholar
• RukmangadacharLAMakhariaGKMishraAProteome analysis of the macroscopically affected colonic mucosa of Crohn’s disease and intestinal tuberculosisSci Rep201662316210.1038/srep2316226988818
   PubMed Web of Science ®Google Scholar
• SehrawatUPokhriyalRGuptaAKProteomic analysis of advanced ovarian cancer tissue to identify potential biomarkers of responders and nonresponders to first-line chemotherapy of carboplatin and paclitaxelBiomark Cancer20161684356
   Google Scholar
• RukmangadacharLAKatariaJHariprasadGTwo-dimensional difference gel electrophoresis (DIGE) analysis of sera from visceral leishmaniasis patientsClin Proteomics201181410.1186/1559-0275-8-221906353
   PubMedGoogle Scholar
• KatariaJRukmangadacharLAHariprasadGTwo dimensional difference gel electrophoresis analysis of cerebrospinal fluid in tuberculous meningitis patientsJ Proteomics201174102194220310.1016/j.jprot.2011.06.02021723968
   PubMed Web of Science ®Google Scholar
• ManralPSharmaPHariprasadGChandralekhaTMSrinivasanACan apolipoproteins and complement factors be biomarkers of Alzheimer’s disease?Curr Alzheimer Res20129893594322631439
   PubMed Web of Science ®Google Scholar
• ChahineLMSternMBChen-PlotkinABlood-based biomarkers for Parkinson’s diseaseParkinsonism Relat Disord201420S99S10310.1016/S1353-8020(13)70025-724262199
   PubMedGoogle Scholar
• SabherwalSEnglishJAFöckingMCagneyGCotterDRBlood biomarker discovery in drug-free schizophrenia: the contribution of proteomics and multiplex immunoassaysExpert Rev Proteomics201613121141115510.1080/14789450.2016.125226227771981
   PubMed Web of Science ®Google Scholar
• HalperinIMorelliMKorczynADBiomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer’s and Parkinson’s diseasesNeurotherapeutics20096112814010.1016/j.nurt.2008.10.03319110204
   PubMed Web of Science ®Google Scholar
• LakhanSEKramerASchizophrenia genomics and proteomics: are we any closer to biomarker discovery?Behav Brain Funct20095210.1186/1744-9081-5-219128481
   PubMed Web of Science ®Google Scholar
• SabherwalSEnglishJAFockingMBlood biomarker discovery in drug-free schizophrenia: the contribution of proteomics and multiplex immunoassaysExpert Rev Proteomics201613121141115510.1080/14789450.2016.125226227771981
   PubMed Web of Science ®Google Scholar
• HariprasadGGuptaAKPokhriyalRKCerebrospinal fluid proteomics for identification of potential biomarkers to monitor pharmacological therapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophreniaFASEB J2018321 Suppl
   Web of Science ®Google Scholar
• GuptaAKRaniKSwarnkarSEvaluation of serum apolipoprotein E as a potential biomarker for pharmacological therapeutic efficacy monitoring in dopamine dictated disease spectrum of schizophrenia and Parkinson’s diseaseJ Cent Nerv Syst Dis2018101810.1177/1179573518803585
   Web of Science ®Google Scholar
• ChouKLTaylorJLPatilPGThe MDS–UPDRS tracks motor and non–motor improvement due to sub-thalamic nucleus deep brain stimulation in Parkinson diseaseParkinsonism Relat Disord2013191196696910.1016/j.parkreldis.2013.06.01023849499
   PubMed Web of Science ®Google Scholar
• GoetzCGPoeweWRascolOMovement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendationMov Disord2004191020102810.1002/mds.2021315372591
   PubMed Web of Science ®Google Scholar
• JancaAUstünTBEarlyTSSartoriusNThe ICD-10 symptom checklist: a companion to the ICD-10 classification of mental and behavioural disordersSoc Psychiatry Psychiatr Epidemiol19932852392428284737
   PubMed Web of Science ®Google Scholar
• LokeJHHarleyVLeeJBiological factors underlying sex differences in neurological disordersInt J Biochem Cell Biol20156513915010.1016/j.biocel.2015.05.02426028290
   PubMed Web of Science ®Google Scholar
• ShamPCMacLeanCJKendlerKSA typological model of schizophrenia based on age at onset, sex and familial morbidityActa Psychiatr Scand19948921351418178665
   PubMed Web of Science ®Google Scholar
• GoldsteinDSHolmesCSharabiYCerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson disease and other synucleinopathiesBrain2012351900191310.1093/brain/aws055
   Web of Science ®Google Scholar
• MillerCKirchmairRTrogerJCSF of neuroleptic-naive first-episode schizophrenic patients: levels of biogenic amines, substance P, and peptides derived from om chromogranin A (GE-25) and secretogranin II (secretoneurin)Biol Psychiatry1996391191191810.1016/0006-3223(95)00098-49162202
   PubMed Web of Science ®Google Scholar
• RocheSTiersLProvansalMDepletion of one, six, twelve or twenty major blood proteins before proteomic analysis: the more the better?J Proteomics200972694595110.1016/j.jprot.2009.03.00819341827
   PubMed Web of Science ®Google Scholar
• ZolotarjovaNMartosellaJNicolGDifferences among techniques for high-abundant protein depletionProteomics20055133304331310.1002/pmic.20040202116052628
   PubMed Web of Science ®Google Scholar
• SteelLFTrotterMGNakajimaPBEfficient and specific removal of albumin from human serum samplesMol Cell Proteomics20032426227010.1074/mcp.M300026-MCP20012754305
   PubMed Web of Science ®Google Scholar
• SinhaAPatelSShuklaRSinghMPBlood proteome profiling in case controls and Parkinson’s disease patients in Indian populationClin Chim Acta200738023223410.1016/j.cca.2007.02.01317367770
   PubMed Web of Science ®Google Scholar
• PritloveDCGuMBoydCARandevaHSVatishMNovel placental expression of 2,3-bisphosphoglycerate mutasePlacenta200627892492710.1016/j.placenta.2005.08.01016246416
   PubMed Web of Science ®Google Scholar
• VarçinMBenteaEMichotteYOxidative stress in genetic mouse models of Parkinson’s diseaseOxid Med Cell Longev20122012
   Web of Science ®Google Scholar
• IlićTJovanovićMJovicićATomovićMOxidative stress and Parkinson’s diseaseVojnosanit Pregl19985554634689921070
   PubMedGoogle Scholar
• YaoJKKeshavanMSAntioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative viewAntioxid Redox Signal20111572011203510.1089/ars.2010.360321126177
   PubMed Web of Science ®Google Scholar
• KoziorowskiDTomasiukRSzlufikSFriedmanAInflammatory cytokines and NT-proCNP in Parkinson’s disease patientsCytokine201260376276610.1016/j.cyto.2012.07.03022910321
   PubMed Web of Science ®Google Scholar
• MüllerNSchwarzMJImmune system and SchizophreniaCurr Immunol Rev20106321322021057585
   PubMedGoogle Scholar
• SudhaKRaoAVRaoSRaoAFree radical toxicity and antioxidants in Parkinson’s diseaseNeurol India2003511606212865518
   PubMed Web of Science ®Google Scholar
• PretoriusESwanepoelACBuysAVEryptosis as a marker of Parkinson’s diseaseAging (Albany NY)201461078881910.18632/aging.10069525411230
   PubMedGoogle Scholar
• BiagioliMPintoMCesselliDUnexpected expression of alpha-and beta-globin in mesencephalic dopaminergic neurons and glial cellsProc Natl Acad Sci U S A200910636154541545910.1073/pnas.081321610619717439
   PubMed Web of Science ®Google Scholar
• CodrichMBertuzziMRussoRNeuronal hemoglobin affects dopaminergic cells’ response to stressCell Death Dis201781e253810.1038/cddis.2017.51828055011
   PubMed Web of Science ®Google Scholar